GSK’s RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older
RSV affects over six million people aged 60 and older in China each yearGlaxoSmithKline plc (GSK)">Weiter zum vollständigen Artikel bei GlaxoSmithKline plc (GSK)
Quelle: EN, GlaxoSmithKline